Natixis CIB successfully completes €230m syndicated term loan facility for Fosun Pharma
Natixis Corporate & Investment Banking (Natixis CIB) is pleased to have successfully completed a EUR230m 3-year syndicated term loan facility for Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma).
Natixis CIB acted as the sole Mandated Lead Arranger, Underwriter and Bookrunner on the syndicated facility for Fosun Industrial Co., Limited, a wholly owned subsidiary of Fosun Pharma. Based on the strong market response, the syndicated facility was upsized from EUR200m to EUR230m. Proceeds of the facility will be used for general corporate purposes, including, but not limited to, the funding of general working capital requirements and the refinancing of existing debt.
Fosun Pharma is one of the largest healthcare companies in China, with a market-leading position in the medical and pharmaceutical industries. It possesses a full industrial value chain, including pharmaceutical manufacturing, healthcare services, medical devices and diagnosis, and pharmaceutical and retail distribution.
“We are proud to partner with Fosun Pharma on this transaction as the sole underwriter. Being part of the strong mix of seven international and Chinese lenders in the syndicated facility highlights the value of Natixis CIB’s global platform and our strong financing expertise. The deal also highlights that the fact that there continues to be healthy levels of liquidity available to strategic private enterprises in China with good credit profiles,” said Hong Liu, Senior Country Manager, Greater China, for Natixis CIB.
"This transaction underscores our leadership and capabilities in the healthcare industry in China," added Nicholas Low, Head of Healthcare Industry Group Asia Pacific for Natixis CIB. "China and the wider Asia Pacific healthcare industry is at an inflection point, driven by a confluence of supportive demographics, evolving healthcare policies, improved resource allocation and importantly, innovation fuelling sector growth in the coming years."
Natixis Corporate & Investment Banking is a leading global financial institution that provides advisory, investment banking, financing, corporate banking and capital markets services to corporations, financial institutions, financial sponsors and sovereign and supranational organizations worldwide.
Our teams of experts in close to 30 countries advise clients on their strategic development, helping them to grow and transform their businesses, and maximize their positive impact. Natixis CIB is committed to aligning its financing portfolio with a carbon neutrality path by 2050 while helping its clients reduce the environmental impact of their business.
As part of the Global Financial Services division of Groupe BPCE, the second largest banking group in France through the Banque Populaire and Caisse d’Epargne retail networks, Natixis CIB benefits from the Group’s financial strength and solid financial ratings (Standard & Poor's: A, Moody's: A1, Fitch: A+, R&I: A+).
